AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
Retrieved on:
Friday, December 2, 2022
NYSE, Immunology, EAP, CFS, Congress, COVID-19, Degenerative disease, Society, Special access program, PSLRA, Erasmus MC, ME/CFS, Research, Cancer, AIM, Therapy, Inspectorate, Patient, Pancreatic cancer, Disease, British Society for Neuroendocrinology, Chronic fatigue syndrome, Rintatolimod, Immune system, Pharmaceutical industry
OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.
Key Points:
- OCALA, Fla., Dec. 02, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (AIM or the Company), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced its abstract has been accepted for poster presentation at the British Society for Immunology Congress 2022 being held December 5-8, 2022 in Liverpool, UK.
- Smidt - Centre for Human Drug Research, Leiden, the Netherlands
For more information, please visit the Congress website, here . - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19.
- The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.